KOSPIBiotech & Pharma326030

SK biopharmaceuticals

₩86,400▼ 2.92%2026-11-18 close
Market Cap
₩6.8T
Turnover
₩13.5B
Volume
160K
Shares out.
78.3M
PER
18.1×
PBR
—
EPS
₩4,867
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Cenobamate's global rollout and mixed profit trends

US direct sales of cenobamate and its Asian launches lifted SK Biopharmaceuticals' operating profit in 3Q 2026, while net profit attributable to controlling shareholders has fallen for three straight quarters since its 4Q 2025 peak.

  1. 1

    Operating profit in 3Q 2026 was KRW 116.3 billion, up 65.9% year on year, while revenue rose 34.8% to KRW 258.4 billion.

  2. 2

    Net profit attributable to controlling shareholders peaked at KRW 136.6 billion in 4Q 2025 and declined to KRW 54.3 billion in 3Q 2026, moving in the opposite direction to operating profit.

  3. 3

    Cumulative US sales of cenobamate for the first three quarters reached USD 441.3 million, about 76% of the top of the annual guidance range of USD 550 million to USD 580 million, which the company kept unchanged.

  4. 4

    Cenobamate launched in China in March 2026, in Korea in early November 2026, and in Japan on 13 November 2026, completing a three-country launch in Northeast Asia.

  5. 5

    The next checkpoints are the FDA review of the PGTC indication filed on 3 November 2026 and the first top-line results of the RISE3 trial for BHV-7000, which the company expects by the end of 2026.

02

Business structure

SK Biopharmaceuticals' core product is cenobamate, sold in the US as XCOPRI. In the US, its subsidiary SK Life Science sells the product directly, while other major markets are served through regional partners.

According to the preliminary 3Q 2026 results the company announced on 5 November 2026, US sales of cenobamate in 3Q 2026 were USD 156.81 million (about KRW 223.6 billion), up 26.4% year on year.

Other revenue in the same quarter was KRW 34.8 billion, made up of KRW 5.9 billion in finished and API product sales and KRW 28.9 billion in service revenue. Service revenue includes royalty income as well as revenue from Asian clinical activities and milestone payments.

Because the model relies on royalties, overseas income moves with the local sales results of partners. In Japan, partner Ono Pharmaceutical began sales on 13 November 2026. Japan is the second-largest single-country epilepsy market after the US, with an estimated 1 million patients.

The product launched in China in March 2026 and in Korea in early November 2026, and it is approved in about 50 countries and regions, including the US and Europe. The epilepsy treatment market is built on established anti-seizure drugs, so expanding prescription share is central to growth. The company has said it will extend its US direct sales network to a second product.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩191.7B₩70.1B36.6%
2025Q4₩194.4B₩46.3B23.8%
2026Q1₩227.9B₩89.8B39.4%
2026Q2₩247.4B₩97.1B39.2%
2026Q3₩258.4B₩116.3B45.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩246.2B-₩131.1B-₩139.4B−53.2%−44.0%109.8%
2023₩354.9B-₩37.5B-₩35.4B−10.6%−12.5%125.3%
2024₩547.6B₩96.3B₩240.7B17.6%44.1%80.6%
2025₩706.7B₩203.9B₩267B28.9%32.8%45.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 246.2 billion in 2022 to KRW 354.9 billion in 2023 (up 44.2% year on year), KRW 547.6 billion in 2024 (up 54.3%), and KRW 706.7 billion in 2025 (up 29.1%). Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022-2025 period.

Operating results moved from an operating loss of KRW 131.1 billion in 2022 to an operating loss of KRW 37.5 billion in 2023, a narrower deficit, and then to operating profit of KRW 96.3 billion in 2024, a turn to profitability. Operating profit in 2025 was KRW 203.9 billion, up 111.7% year on year.

The operating margin rose from -53.2% in 2022 to -10.6% in 2023, 17.6% in 2024 and 28.9% in 2025. Net profit attributable to controlling shareholders turned positive at KRW 240.7 billion in 2024 and grew 10.9% to KRW 267 billion in 2025.

Net profit including non-controlling interests in 2025 was KRW 253.3 billion, a different figure from the controlling-shareholder number, and the gap reflects non-controlling interests.

The debt ratio (total liabilities divided by total equity) fell from 109.8% in 2022 to 45.0% in 2025, and operating cash flow turned positive at KRW 94.9 billion in 2024 and reached KRW 176.3 billion in 2025.

On a quarterly basis, revenue rose for four consecutive quarters from 4Q 2025 through 3Q 2026, reaching KRW 258.4 billion in 3Q 2026.

Operating profit bottomed at KRW 46.3 billion in 4Q 2025 and then rose for three consecutive quarters, to KRW 89.8 billion in 1Q 2026, KRW 97.1 billion in 2Q 2026, and KRW 116.3 billion in 3Q 2026.

The company said quarterly operating profit exceeded KRW 100 billion for the first time, excluding quarters that included one-off service revenue.

Net profit attributable to controlling shareholders peaked at KRW 136.6 billion in 4Q 2025 and then declined for three consecutive quarters, to KRW 105.2 billion in 1Q 2026, KRW 85.1 billion in 2Q 2026 and KRW 54.3 billion in 3Q 2026.

Operating profit in 3Q 2026 rose 65.9% year on year, while net profit attributable to controlling shareholders fell 26.7%, so the two measures moved in opposite directions. The concentration of gross-to-net deductions in 4Q is a seasonal factor to consider when reading fourth-quarter profit swings.

Net profit attributable to controlling shareholders for the four quarters from 4Q 2025 through 3Q 2026 totaled KRW 381.2 billion.

05

Industry analysis

The epilepsy treatment market is largest in the US, and Japan is considered the second-largest single-country market in the world. Japan's patient population is estimated at about 1 million.

Cenobamate's main indication is adult patients with partial-onset seizures that are not well controlled by existing anti-seizure drugs.

In the US, prescriptions rose so that the monthly average number of prescriptions exceeded 50,000 for the first time in 3Q 2026, and new-patient prescriptions held at about 1,800 per month. These figures are the company's reported data.

On the supply side, the concentration of gross-to-net deductions in the fourth quarter is a factor behind quarterly swings. In terms of competition, Samsung Biologics operates mainly as a contract manufacturer, so its business model differs from SK Biopharmaceuticals'.

SK Biopharmaceuticals sells its developed drug directly in the US, and the company has described this as a path with few precedents. In Japan, a partner handles sales, so revenue is recorded mainly as royalties. Over the longer term, the effect of patent expiry and generic entry on pricing is a separate issue to monitor.

06

Outlook

The company kept its 2026 annual US sales guidance for cenobamate at USD 550 million to USD 580 million. Cumulative US sales for the first three quarters reached USD 441.3 million, about 76% of the top of the range.

The company said that, given the growth trend, reaching the top of the range had become more likely, but it kept the guidance in view of the concentration of gross-to-net deductions in the fourth quarter. Cumulative other revenue through 3Q 2026 was about KRW 88.0 billion against annual guidance of KRW 110.0 billion.

Cumulative selling, general and administrative expenses were KRW 392.2 billion, about 69% of the KRW 570.0 billion annual guidance.

On lifecycle management, a pediatric partial-onset seizure filing was submitted to the FDA in October 2026, a supplemental application for the primary generalized tonic-clonic seizure (PGTC) indication was submitted on 3 November 2026, and an oral suspension application was submitted in March 2026, and all are under FDA review.

The PGTC filing rests on a global Phase 3 study of 169 patients at 122 sites in 12 countries, in which the median seizure frequency fell 71.9% from baseline versus a 39.6% decline in the placebo group. The company expects royalty income to begin as sales in Japan grow.

On new products, the company signed an agreement to in-license BHV-7000 (oparkalim) from Biohaven, and the closing process is under way. The first top-line results of the pivotal RISE3 trial are expected by the end of 2026. The company plans to file two to three investigational new drug applications in 2027.

07

Valuation

PER
18.1×
PBR
—
ROE
44.7%
EPS
₩4,867
BPS
—
Dividend per share
₩0

A factual starting point for valuation is to look at earnings trends together with the level relative to net assets.

Net profit attributable to controlling shareholders for the four quarters from 4Q 2025 through 3Q 2026 totaled KRW 381.2 billion, and the market capitalization sits in a high range relative to that earnings total.

Net profit attributable to controlling shareholders has declined for three consecutive quarters since its 4Q 2025 peak, while operating profit has risen for three consecutive quarters, so earnings-based multiples read differently depending on which profit measure is used.

Measured against the controlling-shareholder equity of KRW 813 billion at the end of 2025, the share price stands at a premium to net assets.

The dividend yield is in the 0% range, so shareholder returns are centered on reinvestment rather than dividends, and the company has said cash from cenobamate sales will be reinvested in R&D and new product in-licensing.

When comparing with other companies in the sector, direct selling and contract manufacturing differ in growth stage and business model, which makes simple multiple comparisons difficult.

Over the years, the company moved from losses to profits and its profit recovery has been uneven, so the earnings trend is the central reference for interpreting multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Continued growth in US direct sales

US sales of cenobamate in 3Q 2026 were USD 156.81 million, up 26.4% year on year. Cumulative US sales for the first three quarters reached USD 441.3 million, about 76% of the top of the annual guidance range.

Total US prescriptions in 3Q 2026 were about 152,000, up 6.0% from the prior quarter, and the monthly average exceeded 50,000 for the first time. The widening prescription base is cited as the main bullish factor.

Operating leverage and margin gains

The operating margin rose to 28.9% in 2025 from 17.6% in 2024. Operating profit in 3Q 2026 was KRW 116.3 billion, up 65.9% year on year.

Selling, general and administrative expenses in 3Q 2026 were KRW 133.1 billion, down KRW 2.1 billion from the prior quarter, and the company attributed profit growth to operating leverage in its direct sales model.

The company cites the fact that operating profit rose even as the won-dollar exchange rate declined as evidence of structural improvement.

Asian launches and expected royalty income

Cenobamate launched in China in March 2026, followed by Korea in early November 2026 and Japan on 13 November 2026, completing a three-country presence in Northeast Asia.

Japan is the second-largest epilepsy market with an estimated 1 million patients, Ono Pharmaceutical handles sales there, and the company expects royalty income linked to local sales. Pediatric, PGTC and oral suspension filings are also under review.

09

Bear factors

Consecutive declines in controlling-shareholder net profit

Net profit attributable to controlling shareholders kept declining quarter after quarter through 3Q 2026. In 3Q 2026 it fell 26.7% year on year, moving opposite to operating profit. The items behind this gap should be checked in the detailed income statement lines of the periodic report. The need for a clearer explanation of earnings quality is cited as a bearish factor.

Fourth-quarter deductions and guidance interpretation

The company said reaching the top of the guidance range had become more likely, yet it kept the guidance because of the gross-to-net deductions concentrated in the fourth quarter. Operating profit fell 34.0% quarter on quarter in 4Q 2025, which may be linked to this seasonal pattern. The size of fourth-quarter profit therefore remains uncertain.

Single-product dependence and one-off income

Cenobamate remains the center of the company's revenue. Of the KRW 34.8 billion in other revenue in 3Q 2026, KRW 28.9 billion was service revenue, which includes contract-linked income such as royalties and milestones. The company said some quarterly operating profit included one-off service revenue. Results from the follow-on pipeline asset BHV-7000 have not yet been reported.

10

Risk factors

Regulatory timing

The PGTC indication was filed with the FDA on 3 November 2026, the pediatric partial-onset seizure expansion in October 2026, and the oral suspension in March 2026. Decision timing for all three has not been set, so the effect of indication and formulation expansion on reported results could be delayed.

Dizziness and somnolence are the main reported adverse reactions, and safety evaluation will continue to accompany prescription growth.

Currency translation risk

Cenobamate sales are earned in dollars but reported in won, so currency moves affect results. In 3Q 2026, dollar-denominated sales rose 4.9% from the prior quarter, while won-denominated sales fell 0.3%. In a period of weaker dollar exchange rates, won-based revenue can be pressured.

Concentration and partner dependence

The company's revenue is concentrated in one product, cenobamate. Income from Japan, China and Korea depends on partner sales and royalty terms. The BHV-7000 in-licensing deal is still in the closing process, and if the trial results fall short, the pace of pipeline expansion could slow.

11

What to watch next

  1. By end of 2026

    First top-line results of the pivotal RISE3 trial for BHV-7000. The company expects them by year-end, and they will determine progress of its second product pipeline.

  2. Closing date not yet set

    Completion of the BHV-7000 in-licensing transaction. The US direct sales network for a second product only becomes operational after closing.

  3. By end of March 2027

    Filing of the 2026 annual report. This is the point to confirm whether US cenobamate sales landed within the USD 550 million to USD 580 million guidance and what the operating margin was after fourth-quarter deductions.

  4. Decision timing not yet set (filed 3 November 2026)

    The FDA decision on the PGTC indication. If approved, cenobamate's treatment scope would extend from partial-onset seizures to primary generalized tonic-clonic seizures.

  5. During 2027

    Whether the company files the targeted two to three investigational new drug applications, and when and how much royalty income from Japanese sales appears in results.

12

Overall view

SK Biopharmaceuticals' operating profit in 3Q 2026 was KRW 116.3 billion, up 65.9% year on year, and the expansion of US direct sales of cenobamate was the main driver. The operating margin improved from -53.2% in 2022 to 28.9% in 2025, and the debt ratio fell from 109.8% to 45.0% over the same period.

On the other side, net profit attributable to controlling shareholders peaked at KRW 136.6 billion in 4Q 2025 and fell to KRW 54.3 billion in 3Q 2026, a third straight quarterly decline, so it moved in the opposite direction to operating profit.

The 2026 US sales guidance was kept at USD 550 million to USD 580 million, and cumulative sales through three quarters were about 76% of the top of the range.

Launches followed in China in March 2026, Korea in early November 2026, and Japan on 13 November 2026, but the timing and size of royalty income from Japan have not yet appeared in results.

In the pipeline, FDA reviews of the PGTC, pediatric and oral suspension filings are under way, and the first RISE3 top-line results for BHV-7000 are expected by the end of 2026.

Bullish factors are direct-sales growth and cost leverage, while bearish factors are the decline in net profit, dependence on a single product, and the weight of one-off service revenue.

The next checkpoints are whether cenobamate sales meet guidance in the 2026 annual report and how selling, general and administrative expenses and R&D spending trend.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. g-enews.com
  2. view.asiae.co.kr
  3. kr.investing.com
  4. fnnews.com
  5. sentv.co.kr
  6. asiatime.co.kr
  7. newspim.com
  8. pharmnews.com
  9. sentv.co.kr
  10. hankyung.com
  11. newswire.co.kr
  12. vegannews.co.kr
  13. specialtimes.co.kr
  14. efnews.co.kr
  15. news.mtn.co.kr
  16. ddaily.co.kr
  17. mydaily.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis